Alnylam Pharmaceuticals Q1 2026 Financial Results: Key Highlights for Investors
Alnylam Pharmaceuticals Reports Strong Q1 2026 Results: Key Insights for Investors
Summary of Results
Alnylam Pharmaceuticals, Inc. has reported its financial results for the quarter ended March 31, 2026, demonstrating robust growth across product revenues and significant improvements in profitability. The company also reiterated its full-year 2026 guidance, signaling confidence in continued operational and commercial momentum.
Key Financial Highlights
- GAAP Income from Operations: \$268.6 million for Q1 2026, a substantial turnaround from a loss in the prior year period (the percentage change is indicated as greater than 500%).
- GAAP Net Income: \$206.0 million for Q1 2026, a dramatic improvement compared to a net loss of \$15.9 million in Q1 2025.
- Non-GAAP Net Income: \$273.0 million for Q1 2026, compared to \$37.9 million in Q1 2025.
- GAAP Diluted EPS: \$1.51 per share, compared to a loss of (\$0.14) per share in Q1 2025.
- Non-GAAP Diluted EPS: \$1.99 per share, compared to \$0.29 per share in Q1 2025.
- Cash and Cash Equivalents: \$1.66 billion as of March 31, 2026, with total assets of \$5.13 billion and stockholders’ equity of \$1.08 billion.
Revenue Performance
| Product |
Q1 2026 Net Revenue Growth (YoY) |
Comment |
| AMVUTTRA |
+187% |
Strong global launch and expanded use in ATTR-CM |
| ONPATTRO |
-59% |
Decline, offset by AMVUTTRA uptake |
| GIVLAARI |
+11% |
Continued growth in rare disease segment |
| OXLUMO |
+22% |
Consistent rare disease demand |
| Total TTR Products |
+153% |
Reflects strong AMVUTTRA launch |
| Total Net Product Revenue |
+121% |
Company-wide growth, driven by new launches |
Operating Expenses and Margins
- Cost of Goods Sold (COGS): Increased to 20% of net product revenues in Q1 2026 (vs. 15% in Q1 2025), driven by higher AMVUTTRA sales and associated royalty rates.
- R&D Expenses: GAAP R&D expenses rose to \$364.9 million (up 38%), reflecting continued investment in pipeline and platform.
- SG&A Expenses: Both GAAP and non-GAAP SG&A increased, primarily due to higher employee compensation and marketing for the AMVUTTRA commercial launch.
Balance Sheet Strength
- Cash Position: \$1.66 billion in cash and cash equivalents, plus \$1.3 billion in marketable debt securities.
- Convertible Debt: \$1.01 billion outstanding.
- Total Equity: \$1.08 billion.
2026 Financial Guidance (Reaffirmed)
- Total Net Product Revenue: \$2.7 billion to \$2.8 billion (using FX rates as of Dec 31, 2025)
- Non-GAAP R&D and SG&A Expenses: \$2.7 billion to \$2.8 billion
- Guidance excludes \$300–\$400 million in stock-based compensation expense from GAAP estimates for R&D and SG&A.
- Growth rates on a constant currency basis are provided for transparency.
Non-GAAP Financial Measures
Alnylam continues to provide non-GAAP measures excluding stock-based compensation and certain non-recurring gains or losses to help investors better understand underlying business performance. The company emphasizes these metrics as they are used internally for performance evaluation, resource allocation, and planning.
Additional Highlights and Shareholder Considerations
- Management reaffirmed confidence in operational performance by reiterating 2026 financial guidance.
- The dramatic improvement in GAAP and non-GAAP profitability, and especially the swing from a net loss to significant net income, could be viewed as materially positive and may impact share price favorably.
- Continued strong global launch of AMVUTTRA, particularly in ATTR-CM, is a key growth driver.
- Increases in SG&A and COGS reflect ongoing commercial investments, but margins remain strong due to revenue growth.
- The balance sheet remains robust, providing flexibility for continued pipeline investment and future strategic initiatives.
- Investors should note that the decline in ONPATTRO revenue has been more than offset by the rapid uptake of AMVUTTRA, indicating successful product transition and market execution.
- Conference call scheduled for April 30, 2026, at 8:30 am ET; webcast available on the investor section of the company website.
Potential Price-Sensitive Information
- Major swing to net profitability: This represents a significant change in the company’s financial profile compared to prior periods and is likely to be viewed positively by investors and analysts.
- AMVUTTRA’s rapid adoption: The exceptional revenue growth from AMVUTTRA is pivotal, solidifying Alnylam’s leadership in the ATTR-CM space and demonstrating execution capability.
- Maintained guidance despite increased costs: The ability to reaffirm full-year guidance even with higher costs suggests underlying business resilience and may support positive share price movement.
Investor Takeaway
Alnylam has delivered a breakout quarter in Q1 2026, driven by the successful launch of AMVUTTRA and robust financial management. The company’s swing to profitability, strong balance sheet, and reaffirmed guidance position it well for continued growth and potential positive share price reaction. Shareholders should closely monitor the ongoing rollout of AMVUTTRA and upcoming pipeline updates, as these will be critical for sustained momentum.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should review the full financial filings and consult with their own advisors before making investment decisions. The information presented is based on the company’s Q1 2026 financial report and may be subject to change or clarification in subsequent disclosures.
View ALNYLAM PHARMACEUTICALS, INC. Historical chart here
